Cognition Therapeutics presents positive biomarker results for Alzheimer's disease treatment.

From GlobeNewswire: 2025-03-25 07:30:00

Cognition Therapeutics, Inc. will present biomarker results from the Phase 2 SHINE study of zervimesine (CT1812) at the AD/PD™ 2025 Alzheimer’s & Parkinson’s Diseases Conference in Vienna, Austria. The study analyzed key proteins in blood samples related to Alzheimer’s disease progression. Dr. Mary Hamby will discuss the impact of zervimesine on disease biology during the conference. The presentation will focus on neurofilament light (NfL) chain, glial fibrillary acidic protein (GFAP), amyloid beta (Aβ), and tau species (p-Tau217 and p-Tau218) biomarkers. Additional details of Cognition’s presentation and posters at AD/PD 2025 are available, showcasing the positive impact of CT1812 treatment on plasma biomarkers and more.



Read more at GlobeNewswire: Cognition Therapeutics to Report Biomarker Results from